Anthocyanins From Sweet Potatoes (<i>Ipomoea batatas</i>): Bioavailability, Mechanisms of Action, and Therapeutic Potential in Diabetes and Metabolic Disorders.

Summary

This review consolidates current evidence on the anthocyanin content of Ipomoea batatas (sweet potato), with particular focus on absorption, metabolism, and proposed mechanisms relevant to diabetes and metabolic dysfunction. The paper likely draws on in vitro, animal, and available human studies to characterise how purple-fleshed sweet potato anthocyanins may modulate glucose metabolism, reduce oxidative stress, and attenuate inflammatory pathways. It represents a useful synthesis for researchers and clinicians interested in functional food components and cardiometabolic health.

UK applicability

Sweet potatoes are not a staple UK crop but are widely consumed and commercially available; findings are broadly applicable to UK dietary guidance and functional food research, particularly in the context of rising type 2 diabetes prevalence and interest in phytonutrient-rich foods.

Key measures

Anthocyanin bioavailability; glycaemic markers (fasting blood glucose, HbA1c); insulin sensitivity indices; inflammatory biomarkers; oxidative stress markers; proposed mechanisms of action

Outcomes reported

The review examines the bioavailability and mechanistic pathways by which sweet potato anthocyanins may exert beneficial effects in diabetes and metabolic disorders. It likely synthesises evidence on glycaemic regulation, insulin sensitivity, oxidative stress, and inflammation as key outcomes.

Topic tags